GE Healthcare announced today that its Discovery* PET/CT 690 and PET VCAR 2.0 were used by Professor Patrick Flamen of the Institut Jules Bordet in Brussels in capturing the Society of Nuclear Medicine and Molecular Imaging 2013 “Image of the Year.” To see the image, visit GE Healthcare’s Newsroom. Professor Flamen’s winning scan illustrated the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease. It was selected as the winning image from more than 2,000 studies. According to SNMMI, it “chooses an image that exemplifies the most cutting-edge nuclear medicine or molecular imaging research today and that demonstrates the ability of molecular imaging to detect, diagnose and treat disease and help select the most appropriate therapy.” “Congratulations to Professor Flamen on this stunning image demonstrating the power of molecular imaging,” said Steve Gray, president and CEO of GE Healthcare’s Molecular Imaging business. “The Institut Jules Bordet continues to be at the forefront of using this technology and GE Healthcare’s Discovery PET/CT 690 is excellent for the image quality and speed desired in these procedures.” “At the Institut Bordet, we aim to provide excellence in both clinical and research activities and we are grateful to the SNMMI for this great recognition,” said Professor Flamen. “GE has been a longtime collaborator in providing great equipment, great applications, and great support, allowing us to achieve outstanding clinical throughput with more than 5,000 PET/CT studies per year on our GE Discovery PET/CT 690.” Institut Jules Bordet, a GE PET/CT European reference center, has showcased its PET/CT imaging best practices to nuclear medicine physicians from around the world. Professor Flamen has supported the development of GE PET VCAR, an exceptional multi-modality and multi-exam comparison application to evaluate lesion metabolic activity over time. The GE Discovery PET/CT 690 is specially designed for speed, efficiency, and PET quantification accuracy. From short exam times through optimized sensitivity system design and comprehensive imaging protocols, the Discovery PET/CT 690 is the first platform focusing on quantification accuracy without compromise by providing intelligent PET and CT iterative reconstruction, respiratory motion management solutions, and integrated PET calibration technologies. PET VCAR 2.0 is the latest visualization and analytical monitoring solution featuring both PERCIST and EORTC standards helping physicians in assessing disease progression or response to therapy.
“This is also a great example of demonstrating the benefit of PET/CT in treatment monitoring,” said Gray. “GE Healthcare is committed in providing technologies, such as our exclusive Q.Suite offering, designed to improve PET quantitative consistency and help contribute to personalized oncology care. This helps to give doctors the ability to assess biological changes in a patient during a course of treatment, allowing them to quickly and accurately modify treatment regimens.”* Trademark of the General Electric Company About GE HealthcareGE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For our latest news, please visit http://newsroom.gehealthcare.com